VivoSeq
Other

Inflammation

1

Pipeline Programs↗

40

Active Trials↗

19

Companies Involved↗

Inflammation is an early-stage landscape with 1 program across 19 companies. The most active players are Novartis, Sirion Therapeutics, Inc., GSK. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

15/100

Mech. Concentration

100/100

Completion Rate

86/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

ApprovedS

Sirion Therapeutics, Inc.

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalA

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

0 programs

PreclinicalH

Halia Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1

Secukinumab

Novartis

Analysis

Trial Status

232

clinical trials

Completed145 · 63%
Recruiting25 · 11%
Unknown status23 · 10%
Terminated14 · 6%
Withdrawn10 · 4%
Active, not recruiting6 · 3%
Other9 · 4%

Clinical Trials

Trial Activity

232 trials

Canadian Study of Arterial Inflammation in Patients With Diabetes and Vascular Events: EvaluatioN of Colchicine
Recruiting·OOttawa Heart Institute Research Corporation·Phase 3·NCT04181996·115 enrolled
PET Imaging of Inflammation and Lipid Lowering Study
Recruiting·UUniversity of Cambridge·N/A·NCT04073797·63 enrolled
Systemic and Central Inflammation in AD
Recruiting·TThe Methodist Hospital Research Institute·Phase 2·NCT06384378·40 enrolled
Molecular Inflammation Board at the Center for Personalized Medicine
Recruiting·UUniversity Hospital Tuebingen·N/A·NCT07132333·3,000 enrolled
Smoldering Inflammation in MS
Recruiting·WWashington University School of Medicine·N/A·NCT06591429·25 enrolled
Skin Barrier Function and Inflammation in Aging: The BIA Study
Recruiting·UUniversity of California, San Francisco·Phase 4·NCT06750653·32 enrolled
Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT05519111·60 enrolled
Belimumab in SLE Synovial Inflammation and Lymph Nodes
Recruiting·—·N/A·NCT06327724·15 enrolled
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Recruiting·—·Phase 1·NCT00595491·313 enrolled
Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD
Recruiting·—·Phase 2·NCT05507242·80 enrolled
Mapping the Effect of (neuro)inflammation on Stress Sensitivity in the Brain of Healthy Men
Recruiting·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT06620679·20 enrolled
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
Recruiting·VVerona Pharma plc·Phase 2·NCT05270525·56 enrolled
Biocollection on Peripheral Inflammation
Recruiting·NNantes University Hospital·N/A·NCT05934474·300 enrolled
Inflammation and Depression in People With HIV
Recruiting·EEmory University·Phase 2·NCT05849038·60 enrolled
grouP O wholE blooD : storagE leSion impacT And infLammation
Recruiting·EEtablissement Français du Sang·N/A·NCT06809010·30 enrolled
Page 1 of 16

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)